HGEN Humanigen Inc

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

$5.90  +0.59 (11.11%)
As of 12/07/2021 14:01:25 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2013
Outstanding shares:  63,818,233
Average volume:  1,491,093
Market cap:   $349,085,735
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    444863203
ISIN:        US4448632038
Sedol:      BM9GXF8
Valuation   (See tab for details)
PE ratio:   -1.44
PB ratio:   7.21
PS ratio:   121.63
Return on equity:   1,334.19%
Net income %:   -8,202.23%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy